QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NVAX

QT70Novavax, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
9.13
-0.37-3.89%
OverviewShort InterestFilings
NVAXQT70Novavax, Inc.·NASDAQ
OverviewShort InterestFilings
9.13-3.89%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.60
Insider Own1.50%
Shs Outstand164.44M
Perf Week1.11%
Market Cap1.56BForward P/E-EPS next Y-0.27Insider Trans0.70%Shs Float-Perf Month2.58%
Enterprise Value1.63BPEG0.15EPS next Q-0.40Inst Own-Short Float-Perf Quarter-6.26%
Income-88418377.00P/S2.62EPS this Y21.35%Inst Trans-Short Ratio-Perf Half Y39.60%
Sales596.35MP/B-EPS next Y42.77%ROA-8.42%Short Interest-Perf YTD35.86%
Book/sh-0.88P/C-EPS next 5Y-ROE89.73%52W High11.97 -23.73%Perf Year40.68%
Cash/sh4.80P/FCF-EPS past 3/5Y-ROIC-9.50%52W Low6.13 48.94%Perf 3Y-
Dividend Est.-EV/EBITDA-38.67Sales past 3/5Y-11.11% 119.58%Gross Margin84.64%Volatility4.44% 4.36%Perf 5Y-
Dividend TTM-EV/Sales2.73EPS Y/Y TTM104.07%Oper. Margin-11.19%ATR (14)0.65Perf 10Y-
Dividend Ex-Date-Quick Ratio2.45Sales Y/Y TTM-12.61%Profit Margin-14.73%RSI (14)47.78Recom2.67
Dividend Gr. 3/5Y-Current Ratio2.48EPS Q/Q-102.05%SMA20-5.11%Beta2.05Target Price18.00
Payout0.00%Debt/Eq-2.04Sales Q/Q-79.01%SMA500.92%Rel Volume1.93Prev Close9.50
Employees952LT Debt/Eq-1.92EarningsAug 05SMA2007.83%Avg Volume4.88MPrice9.13
IPO DateDec 05, 1995Option/ShortYes / YesEPS/Sales Surpr.76.00% 75.00%Net Debt/EBITDA-1.58Volume9,418,793Change-3.89%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-24-25InitiatedCantor FitzgeraldOverweight$174 → $18
Oct-23-25ReiteratedH.C. WainwrightBuy$10 → $11
Aug-20-25DowngradeB of A SecuritiesNeutral → Underperform
Nov-18-24ReiteratedB.Riley Financial$22
Oct-16-24ReiteratedJefferiesBuy$31 → $25
Oct-16-24ReiteratedBank of America Securities$14
Jul-30-24DowngradeJP MorganNeutral → Underweight
Jul-19-24ReiteratedJefferiesBuy$38 → $31
May-10-24ReiteratedH.C. WainwrightBuy$19
May-10-24UpgradeB of A SecuritiesUnderperform → Neutral
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue5961,123682
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A9171203
Gross Profit5051,052479
Selling, General and Administrative Excl. Other129150337
Research and Development345337391
Other Operating Expense9720
Operating Income-66563-249
Interest Expense122320
Unusual Expense
———
Non-Operating Income (Expense)-299-92
Net Income Before Taxes-87442-177
Income Taxes1211
Consolidated Net Income-86440-187
Net Income From Continuing Operations-86440-187
Net Income-86440-187
EPS (Recurring)-0.542.72-1.23
EPS (Basic, Before Extraordinaries)-0.542.72-1.23
EPS (Diluted)-0.602.54-1.23
EBITDA-42492-108
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio—2.65—
Price To Sales Ratio2.500.97—
Gross Margin84.7393.6870.23
Operating Margin-11.0750.13-36.51
Net Margin-14.4339.18-27.42
Shares Outstanding163162152
Market Capitalization1,4881,089—
Operating Lease Expense
———
Insider Trading Volume
$9.94$8.60$7.27$5.93$4.59● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Newton Charles W.DirectorApr 25 '26Option Exercise0.0019,040019,040Apr 28 12:00 AM
Shiver John W.DirectorMar 10 '26Option Exercise0.0015,894015,893Mar 12 12:00 AM
Kelly James PatrickEVP, CFO and TreasurerMar 07 '26Option Exercise0.0024,4460136,503Mar 09 12:00 AM
Draghia-Akli RuxandraEVP, Research & DevelopmentMar 03 '26Option Exercise0.0026,667034,876Mar 05 12:00 AM
Kelly James PatrickEVP, CFO and TreasurerMar 03 '26Option Exercise0.0086,3340145,130Mar 05 12:00 AM
Jacobs John CPresident and CEOMar 03 '26Option Exercise0.00300,3340300,333Mar 05 12:00 AM
O'Hara ElaineEVP, Chief Strategy OfficerMar 03 '26Option Exercise0.00112,6680157,071Mar 05 12:00 AM
Casey Mark JEVP, Chief Legal OfficerMar 03 '26Option Exercise0.0041,5000101,445Mar 05 12:00 AM
Casey Mark JEVP, Chief Legal OfficerMar 01 '26Option Exercise0.008,000065,159Mar 03 12:00 AM
O'Hara ElaineEVP, Chief Strategy OfficerMar 01 '26Option Exercise0.00119,2000111,706Mar 03 12:00 AM
Jacobs John CPresident and CEOMar 01 '26Option Exercise0.00166,6660264,130Mar 03 12:00 AM
Kelly James PatrickEVP, CFO and TreasurerMar 01 '26Option Exercise0.0058,6660130,299Mar 03 12:00 AM
Jacobs John CPresident and CEOJan 23 '26Option Exercise0.00166,3940219,929Jan 26 12:00 AM
Casey Mark JEVP, Chief Legal OfficerDec 11 '25Option Exercise0.0083,798073,972Dec 15 12:00 AM
Draghia-Akli RuxandraSection 16Nov 11 '25Option Exercise0.0014,257014,257Nov 13 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR